AMA announces new CPT codes for Pfizer’s pediatric COVID-19 vaccine
The new product and administration codes are:
- 91308, SARS-CoV-2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use
- 0081A, immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose
- 0082A, …; second dose
The new codes will go into effect if and when the Food and Drug Administration (FDA) grants Pfizer emergency use authorization for its COVID-19 vaccine in children between 6 months and 5 years old. The AMA issued the codes in advance to ensure that healthcare systems are prepared for the potential FDA authorization.
The development of these new codes will enable better tracking, reporting, and analysis of vaccine doses. The CPT code set currently includes 32 unique codes for approved COVID-19 vaccines, including those created by AstraZeneca, Janssen, Moderna, Novavax, and Pfizer. A complete list of CPT codes for COVID-19 vaccines can be found on the AMA website.